How does AOBI's PB Ratio compare to its peers?

Insufficient data to calculate AOBI's Price-To-Book Ratio vs. peers for valuation analysis.

How does AOBI's PB Ratio compare vs other companies in the US Personal Products Industry?

Insufficient data to calculate AOBI's Price-To-Book Ratio vs. industry for valuation analysis.

What is AOBI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate AOBI's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of AOBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate AOBI's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

AOBI Stock Overview

American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. More details

AOBI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($36)

Shares are highly illiquid

Latest financial reports are more than a year old

My Notes

Capture your thoughts, links and company narrative

American Oriental Bioengineering, Inc. Competitors

LifeQuest World

OTCPK:LQWC

US$1.2m

Cyanotech

OTCPK:CYAN

US$2.9m

Nevis Brands

OTCPK:NEVI.F

US$2.1m

Shineco

NasdaqCM:SISI

US$3.2m

Price History & Performance

Summary of share price highs, lows and changes for American Oriental Bioengineering
Historical stock prices
Current Share Price	US$0.0005
52 Week High	US$0.0005
52 Week Low	US$0.0003
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-97.50%
5 Year Change	n/a
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	AOBI	US Personal Products	US Market
7D	0%	-0.8%	-2.1%
1Y	n/a	-25.8%	21.3%

Return vs Industry: Insufficient data to determine how AOBI performed against the US Personal Products industry.

Return vs Market: Insufficient data to determine how AOBI performed against the US Market.

Price Volatility

Is AOBI's price volatile compared to industry and market?
AOBI volatility
AOBI Average Weekly Movement	n/a
Personal Products Industry Average Movement	8.1%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.8%
10% least volatile stocks in US Market	3.2%

Stable Share Price: AOBI has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine AOBI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Tony Liu	n/a

American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting. It also offers over-the-counter pharmaceutical products comprising Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS) and other PMS and menopause-related symptoms; and Boke Nasal Spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis.

American Oriental Bioengineering, Inc. Fundamentals Summary

How do American Oriental Bioengineering's earnings and revenue compare to its market cap?
AOBI fundamental statistics
Market cap	US$36.00
Earnings (TTM)	-US$91.02m
Revenue (TTM)	US$121.58m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is AOBI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AOBI income statement (TTM)
Revenue	US$121.58m
Cost of Revenue	US$84.32m
Gross Profit	US$37.26m
Other Expenses	US$128.28m
Earnings	-US$91.02m

Last Reported Earnings

Sep 30, 2013

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did AOBI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/09/20 10:32
End of Day Share Price	2023/06/23 00:00
Earnings	2013/09/30
Annual Earnings	2012/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

American Oriental Bioengineering, Inc. is covered by 9 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ye Yin	Brean Capital
Julie Chen	CRT Capital Group
Julie Chen	Hudson Securities Inc.